Case Study: RedHill Biopharma achieves 100% reduction in COVID-19 hospitalizations with ObvioHealth

RedHill Biopharma - Customer Case Study

RedHill Biopharma engaged ObvioHealth to run a decentralized COVID‑19 trial that minimized patient burden and exposure while maintaining close clinical oversight. RedHill needed to recruit patients in hot spots, monitor vitals for safety and efficacy, and conduct clinician assessments; ObvioHealth delivered a hybrid design using home health visits, electronic patient‑reported outcomes (ePRO), and remote digital monitoring devices.

ObvioHealth implemented digital hotspot recruitment in the U.S. and South Africa, on‑site enrollment and training, three at‑home monitoring devices (temperature, oxygen saturation, ECG) feeding directly into its system, optional home health or on‑site visits for sample collection, and daily then thrice‑weekly ePRO. The study followed patients daily for two months, produced successful endpoints in early 2022 that enabled regulatory discussions, and delivered measurable impact—100% reduction in hospitalizations and an 87.8% reduction in reported new severe COVID‑19 symptoms.

RedHill Biopharma

Terry Plasse

Medical Director